Etaracizumab, formerly known as MEDI523 and subsequently LM609, represents a unique strategy in immune therapy. This monoclonal antibody is intended to precisely block the activity of complement factor , a essential component of the cascade involved in tissue damage. Data have explored its therapeutic use in several chronic conditions , with early